LM22A-4

Research use only, not for human use.

LM22A-4 is a brain-derived neurotrophic factor (BDNF) mimetic and agonist of the receptor tropomyosin-related kinase B (TrkB; IC50 : 47 nM in a fluorescence anisotropy assay).

LM22A-4 is a brain-derived neurotrophic factor (BDNF) mimetic and agonist of the receptor tropomyosin-related kinase B (TrkB; IC50 : 47 nM in a fluorescence anisotropy assay).

LM22A-4 significantly up-regulates OPN and ALPase mRNA expression in a dose-dependent manner and OC mRNA level is significantly increased by 5 μM of LM22A-4. LM22A-4 significantly increases OPN, ALPase and OC mRNA expression in a time-dependent manner. LM22A-4 stimulated OPN and OC mRNA expression in HCEM cells cultured with mineralizing media.

LM22A-4 (10 mg/kg, i.p.) significantly reduces the degree of tissue injury and apoptosis (TUNEL staining and caspase-3 and Bcl-2 expression) compared with vehicle treated group. LM22A-4 also significantly ameliorates the recovery of limb function. LM22A-4 (10 mg/kg) treatment results in a significant increase in neuron number. LM22A-4 administration (10 mg/kg) significantly improves the neurological scores compared with those of the solvent-treated animals.

——

Tyrosine Kinase

Trk Receptor

Trk

——

——

37988-18-4

339.34

C15H21N3O6

>98% (HPLC)

H2O:50 mg/mL (147.34 mM);DMSO:29 mg/mL (85.46 mM)

O=C(NCCO)c1cc(C(=O)NCCO)cc(C(=O)NCCO)c1

——

(-20℃)

With Ice Pack

≥ 2 years